Efficacy of Apraclonidine 0.5% in the Diagnosis of Horner Syndrome in Pediatric Patients Under Low or High Illumination

American Journal of Ophthalmology

Volumn 142, Issue 3, 2006, Pages

  Chen, Po Liang ^a,b   Hsiao, Chih Hsien ^a,b   Chen, Jiann Torng ^a,b   Lu, Da Wen ^a,b   Chen, Win Ying ^a,c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

APRACLONIDINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CLONIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ADOLESCENT; ANISOCORIA; ARTICLE; CHILD; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; FEMALE; HORNER SYNDROME; HUMAN; ILLUMINATION; MALE; MEDICAL RECORD; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT; DARK ADAPTATION; INFANT; LIGHT; PHOTOGRAPHY; PRESCHOOL CHILD; PUPIL;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; CHILD; CHILD, PRESCHOOL; CLONIDINE; DARK ADAPTATION; FEMALE; HORNER SYNDROME; HUMANS; INFANT; LIGHT; MALE; PHOTOGRAPHY; PUPIL;

EID: 33748858719     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2006.04.052     Document Type: Article

References (22)

1. Thompson H.S., and Miller N.R. Disorders of papillary function, accommodation, and lacrimation. In: Walsh F.B., and Hoyt W.F. (Eds). Clinical neuro-ophthalmology. 5th ed. (1969), Williams & Wilkins, Baltimore, Maryland 514-521
2. Pilley S.F.J., and Thomposon H.S. Pupillary "dilation lag" in Horner syndrome. Br J Ophthalmol 59 (1975) 731-735
3. Jeffery A.R., Ellis F.J., Repka M.X., and Buncic J.R. Pediatric Horner syndrome. J AAPOS 2 (1998) 159-167
4. Morales J., Brown S.M., Abdul-Rahim A.S., and Crosson C.E. Ocular effects of apraclonidine in Horner syndrome. Arch Ophthalmol 118 (2000) 951-954
5. Brown S.M., Aouchiche R., and Freedman K.A. The utility of 0.5% apraclonidine in the diagnosis of Horner syndrome. Arch Ophthalmol 121 (2003) 1201-1203
6. Bacal D.A., and Levy S.R. The role of apraclonidine in the diagnosis of Horner syndrome in pediatric patients. Arch Ophthalmol 122 (2004) 276-279
7. Koc F., Kavuncu S., Kansu T., et al. The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis. Br J Ophthalmol 89 (2005) 1442-1444
8. Kardon R.H., Denison C.E., Brown C.K., and Thompson H.S. Critical evaluation of the cocaine test in the diagnosis of Horner syndrome. Arch Ophthalmol 108 (1990) 384-387
9. Miller P.E., and Rhaesa S.L. Effect of topical administration of 0.5% apraclonidine on intraocular pressure, pupil size, and heart rate in clinically normal cat. Am J Vet Res 57 (1996) 83-86
10. Crosson C.E., Heath A.R., DeVies G.W., and Potter D.E. Pharmacological evidence for heterogeneity of ocular α2 adrenoceptors. Curr Eye Res 11 (1992) 963-970
11. Kardon R. Are we ready to replace cocaine with apraclonidine in the pharmacologic diagnosis of Horner syndrome?. J Neuroophthalmol 25 (2005) 83-85
12. Roatry J.D., and Keltner J.L. Normal pupil size and anisocoria in newborn infants. Arch Ophthalmol 108 (1990) 94-95
13. Robin A.L. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol 105 (1988) 1205-1207
14. Wilhelm H., and Wilhelm B. Clinical applications of pupillography. J Neuroophthalmol 23 (2003) 42-49
15. Kawasaki A., and Kardon R.H. Disorders of the pupil. Ophthalmol Clin North Am 14 (2001) 149-168
16. Lin S.L., and Liang S.S. Evaluation of adverse reaction of aponidine hydrochloride ophthalmic solution. J Ocul Pharmacol Ther 11 (1995) 267-278
17. Yukesl N., Guler C., Caglar Y., and Elibol O. Apraclonidine and clonidine. a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol 16 (1992) 337-342
18. Stewart W.C., Laibovtz R., Horwitz B., et al. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol. Apraclonidine Primary Therapy Study Group. Arch Ophthalmol 114 (1996) 1217-1220
19. Abrams D.A., Robin A.L., Pollack I.P., et al. The safety and efficacy of topical ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol 105 (1987) 1205-1207
20. Carlsen J., Zabriskie N., Known Y., et al. Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 128 (1999) 255-256
21. Enyedi I.B., and Freedman S.F. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 5 (2001) 281-284
22. Stewart W.C., Ritch R., Shin D.H., et al. The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol 113 (1995) 287-292